MC4R and metabolic dysfunction-associated steatotic liver disease: Although no change in steatosis score was observed, the scores of inflammation and ballooning degeneration decreased following treatment with OCA at 10 mg/kg, as indicated by a significant reduction in NAFLD activity score (NAS) in OCA (10 mg/kg)-treated MC4R-KO mice relative to the vehicle-treated group (Fig. 1c).